Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GAAJR
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
uS11998611B2 Ex.23
|
|||||
| Synonyms |
Ex.23
Click to Show/Hide
|
|||||
| Organization |
Cryptophycin antibody conjugates for the treatment of cancer
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2.4
|
|||||
| Antibody Name |
hu2H11_R35-74
|
Antibody Info | Antigen Name |
Undisclosed
|
||
| Payload Name |
Undisclosed
|
|||||
| Therapeutic Target |
Stimulator of interferon genes protein (STING1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The ADMET Data Related to This ADC(2027 Update)
Excretion
| Standard Type | Value | Units | Description | Reference |
|---|---|---|---|---|
| Elimination Half-Life (t1/2) | 6 | h |
By Cathepsin BDrug release by Cathepsin B was evaluated in vitro by incubating the ADC (1.5 ug/mL) in the presence of human Cathepsin B (Calbiochem #219362, 40 ug/mL) in acetate buffer pH 5 at 37°C. for 24 h and detecting the drug by UPLC-MS-SIR-DAD-ELSD. The slope was determined based on the kinetics over the 1st hour, the half-life on the 24 h kinetics.
Click to Show/Hide
|
[1] |